| Literature DB >> 34279911 |
Eftychia Eva Kontou1, Tetiana Gren1, Francisco Javier Ortiz-López2, Emil Thomsen1, Daniel Oves-Costales2, Caridad Díaz2, Mercedes de la Cruz2, Xinglin Jiang1, Tue Sparholt Jørgensen1, Kai Blin1, Pep Charusanti1, Fernando Reyes2, Olga Genilloud2, Tilmann Weber1.
Abstract
Actinobacteria have been a rich source of novel, structurally complex natural products for many decades. Although the largest genus is Streptomyces, from which the majority of antibiotics in current and past clinical use were originally isolated, other less common genera also have the potential to produce a wealth of novel secondary metabolites. One example is the Kutzneria genus, which currently contains only five reported species. One of these species is Kutzneria albida DSM 43870T, which has 46 predicted biosynthetic gene clusters and is known to produce the macrolide antibiotic aculeximycin. Here, we report the isolation and structural characterization of two novel 30-membered glycosylated macrolides, epemicins A and B, that are structurally related to aculeximycin, from a rare Kutzneria sp. The absolute configuration for all chiral centers in the two compounds is proposed based on extensive 1D and 2D NMR studies and bioinformatics analysis of the gene cluster. Through heterologous expression and genetic inactivation, we have confirmed the link between the biosynthetic gene cluster and the new molecules. These findings show the potential of rare Actinobacteria to produce new, structurally diverse metabolites. Furthermore, the gene inactivation represents the first published report to genetically manipulate a representative of the Kutzneria genus.Entities:
Year: 2021 PMID: 34279911 DOI: 10.1021/acschembio.1c00318
Source DB: PubMed Journal: ACS Chem Biol ISSN: 1554-8929 Impact factor: 5.100